In recent years, many laboratories have demonstrated that synthetic, nonviral vectors can be used for in vivo gene delivery. A priori, synthetic vectors have several inherent advantages when compared with viral vectors: they can accommodate large size DNA molecules (therapeutic genes including their endogenous regulatory regions); they are easier to formulate and to produce on a large scale; they can be modified with appropriate ligands that allow specific cell targeting; and they can be administered repeatedly. [1] [2] [3] [4] Until now, many different organic compounds have been tested as synthetic vectors in vitro and in vivo. The most commonly used vectors are based on cationic lipid/DNA complexes (lipoplexes) or cationic polymer/DNA complexes (polyplexes). For lipoplexmediated gene transfer after intravenous (i.v.) injection, different types of cationic lipids with different formulations have been used. 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] For in vivo delivery of polyplexes, poly-l-lysine (PLL) and polyethylenimine (PEI) have been described. [13] [14] [15] [16] [17] [18] Thus, synthetic vectors may soon become a valuable alternative or complementation to viral vectors in gene therapy. At present, however, in vivo expression levels are lower than for viral delivery systems and duration of gene expression is relatively short.
We have started to develop synthetic vectors for i.v. gene delivery, and we were interested to explore specific treatments that would allow an improvement of in vivo gene delivery and expression. One of the major obstacles for i.v. administration of lipoplexes seems to be the uptake and subsequent clearance of circulating lipoplexes by phagocytotic liver macrophages (Kupffer cells). 19 A way to deplete liver macrophages is to administer intravenously liposome-encapsulated clodronate (clodronatelip). 20, 21 Clodronate (dichloromethylene-bisphosphonate) has been widely used for the treatment of osteolytic bone diseases 22 , but cellular uptake of free clodronate is inefficient. Its internalisation, however, is strongly enhanced if the drug is encapsulated in liposomes. Multilamellar clodronate liposomes are preferentially taken up by macrophages in the liver and spleen. Thus, after i.v. injection of clodronate-lip, one can selectively deplete these macrophage populations. 20 An increase in gene expression in the liver, after pretreatment with clodronate-lip, has recently been reported for adenovirusmediated gene delivery [23] [24] [25] but a possible advantageous effect of clodronate-lip treatment for synthetic vectormediated gene delivery has not been described.
Here, we demonstrate that pretreatment of mice with clodronate-lip significantly enhances gene expression after i.v. injection of lipoplexes, whereas polyplexmediated transfection was drastically reduced.
For in vivo analysis of glycerolipoplexes, lipid/DNA complexes (glycerolipid:DOPE at 1:1 molar ratio) were formulated with luciferase reporter plasmids and different cationic glycerolipids: pcTG35, pcTG56, pcTG90 (Figure 1) . At an N/P ratio of 2.5 (see legend of Figure  2 for details), complexes precipitated whereas at ratios of 0.8 and 1.25, they were fairly stable but heterogeneous in size and exhibited only low transfection activity in vitro. N/P ratios of 5 and above yielded stable, homogenous complexes and agarose gel electrophoresis demonstrated complete complexation of DNA. Particle size analysis of such glycerolipoplexes by quasi-elastic light scattering at 90°revealed hydrodynamic diameters between 100 and 200 nm, and electron microscopy of pcTG56 glycerolipoplexes showed particles of 50-60 nm diameter (data not shown, R Bischoff et al, manuscript submitted).
Mice were injected i.v. via the tail vein with pcTG90:DOPE (dioleoylphosphatidyl-ethanolamine) glycerolipoplexes (N/P ratio of 5) containing the luciferase reporter gene plasmids pTG11033 or pCMV-Luc. For pretreatment, mice were injected, 1 day before lipoplex injection with clodronate-lip. One day after glycerolipoplex injection, organs were removed and analysed for luciferase activity. As illustrated in Figure 2 , mice pretreated with clodronate-lip and injected with pcTG90: DOPE/pTG11033 glycerolipoplexes exhibited an approximately seven-fold increase in reporter gene expression in the lung when compared with mice injected with the same complex, but not treated with clodronatelip. In naive (not injected) mice, that received neither clodronate nor glycerolipoplexes, only background levels of luciferase were observed. In other experiments, up to 12-fold enhancement was observed. When we injected complexes that contained pcTG90:DOPE and reporter plasmid pCMV-Luc, higher levels of expression could be observed for both clodronate-lip-treated and non-treated animals compared with mice injected with pTG11033 gly- cerolipoplexes ( Figure 2 ). In this case, the difference between treated and nontreated groups was 2.3-fold, but this difference was statistically not significant in this data set. Besides expression in lung tissue, luciferase expression for pcTG90:DOPE/pCMV-Luc complexes was also observed in heart, spleen and liver, both in clodronate-lip-treated and nontreated animals (data not shown), but at lower levels.
These results demonstrate that pretreatment of mice with clodronate-lip enhanced considerably lipoplexmediated gene expression in the lung after i.v. injection. This enhancement effect has practical implications for the preclinical development of lipoplexes, and adds new aspects to the understanding of the in vivo behaviour of lipoplexes after i.v. injection.
We found that the clodronate-lip pretreatment protocol was useful during the initial steps of the in vivo analysis of new cationic lipids, when formulations have not yet been optimised and expression levels are relatively low. Furthermore, the enhancement effect could be used in cases in which one would like to avoid interference with phagocytotic activities of liver macrophages, for example, during development of lipoplexes for tissue targeting, for testing of tissue-specific promoters other than lung, and for optimisation of formulations to increase circulation times.
Furthermore, our observations add new ideas to current working hypotheses on the in vivo behaviour of lipoplexes. It is generally thought that the lung is the major site of expression, because it represents the first microvasculature which is encountered after i.v. tail vein injection, and that lipoplexes may accumulate due to embolism. 19 Our results suggest an alternative interpretation. Intravenous injection of clodronate-lip has been shown to deplete resident macrophages in liver and spleen, 20 and we verified in our clodronate-lip treatment protocol that liver macrophages were depleted (see below). Thus, if we assume that the clodronate-lip enhancement of gene expression is due to a depletion of macrophages in liver and spleen, our findings indicate that, at least some complexes must circulate in the blood stream before they transfect the lung. Therefore, our findings support the idea of a tropism of cationic lipoplexes for certain endothelia (lung, tumours, inflammation) 26, 27 rather than a simple filtration by the microvasculature.
Alternatively, clodronate-lip may influence the properties of the lung endothelium or its microenvironment, such that lipoplex uptake is enhanced. Also, it is conceivable that clodronate-lip changes the properties of serum, for example, in such a way that the tendency towards aggregation of large complexes is reduced. Although it has been shown that liposomes and lipoplexes can activate complement, 28-30 the inhibition of the complement system by injection of cobra venom and anti-CD3 antibodies did not influence transfection efficiency of lipoplexes after i.v. injection. 8 It is also possible, but less likely, that clodronate-lip depletes a yet not recognised population of phagocytotic cells in the lung or other tissues. It is, however, unlikely that the clodronate-lip effect is due to elimination of macrophages in the lung, because the vast majority of lung macrophages are alveolar macrophages that can only be depleted by pulmonary administration and not by i.v. administration of clodronate-lip. 31 It is interesting to note that in clodronate-lip-treated mice, the relative levels of luciferase expression in the liver (compared with the other organs) were not increased.
When we used a luciferase reporter gene plasmid with a different plasmid backbone (pCMV-Luc), expression levels in the lung were much higher and the enhancement effect of clodronate-lip was less pronounced than for complexes containing plasmid pTG11033. We are currently determining which plasmid elements might be responsible for this difference. One possibility could be that the physical properties of complexes are different for the two plasmids and, as a consequence, transfection of lung tissue is more efficient. In this scenario, less complexes would circulate in the body, and the presumed effect of clodronate-lip (increased half-life) would become less important.
To understand better the effect of clodronate-lip, we determined the time-period for which a clodronate-lip preinjection could affect subsequent glycerolipoplexmediated gene expression. Mice were injected at different times (1, 2, 3, 6 days) with clodronate-lip before injection of pcTG90:DOPE/pTG11033 lipoplexes. One day later, mice were analysed for luciferase expression in the lung. We observed that only preinjection of clodronate-lip 1 day before glycerolipoplex injection (day −1), could enhance expression levels ( Figure 3) . Preinjection of liposome-encapsulated clodronate at days −2, −3 or −6 had no effect on the levels of luciferase expression (Figure 3 ). In the latter cases, expression levels were the same as those observed for mice that were pretreated with empty liposomes.
Depletion of macrophages in the liver was followed by immunohistochemical staining in the same mice, using the monoclonal antibody F4/80 (TEBU, Le Perray-enYvelines, France, RM2901) which detects a 160 kDa plasma membrane component on macrophages and other mononuclear phagocytotic cells. 32 One day after glycerolipoplex injection, macrophages (Kupffer cells) were observed in the liver of mice treated with empty liposomes, similar to non-injected control mice, whereas in mice pretreated at day −1, day −2, day −3, no F4/80-positive cells were detected. In mice treated at day −6, macrophage numbers were lower than for nontreated controls but higher than for those treated at day −1 to day −3. Similar results have been reported by others: after i.v. injection of clodronate-lip, the number of F4/80-positive cells in the liver was reduced for several days and repopulation started between 4 and 8 days after the treatment. 20 Thus, despite the absence of F4/80-positive cells in the liver for about 7 days, a significant enhancement effect of clodronate-lip pretreatment on glycerolipoplex-mediated gene expression lasted only for 1 day. A possible explanation could be that in addition to Kupffer cells, other phagocytotic cells are involved in the clearance of lipoplexes from the blood stream and that these cells rapidly repopulate the liver (or other organs). Alternatively, precursors of macrophages which are negative for the F4/80 marker may repopulate the liver more rapidly. Furthermore, it is possible that the enhancement effect of clodronate-lip is not solely related to the depletion of macrophages (as discussed above).
We were interested to see whether the clodronate effect could also be observed for complexes containing other cationic glycerolipids than pcTG90. As shown in Figure  4 , an enhancement of luciferase expression could also be observed for glycerolipoplexes containing two other multivalent cationic glycerolipids, pcTG35 and pcTG56 (Figure 1 ). For pcTG35 glycerolipoplexes, about nine-fold (at 2 days after injection of lipoplexes), and for pcTG56 glycerolipoplexes, about three-fold enhancement (at 1 day after injection of lipoplexes) could be observed. It should be noted that the formulations for these two cationic lipids have not yet been optimised for maximum in vivo expression. Injection of DNA alone gave luciferase levels that were only slightly above background (about 120 RLU/mg) when compared with non-injected mice. These results demonstrate that the enhancement effect of clodronate is not restricted to lipid pcTG90 but can also be observed for other glycerolipids. Furthermore, we studied the effect of clodronate-lip pretreatment on the efficiency of gene transfer and expression after i.v. injection of polyplexes (DNA complexed with cationic polymers). Intravenous injection of ExGen500 (linear PEI of 22 kDa)/pTG11033 polyplexes resulted in reporter gene expression ( Figure 5 ) in lungs from mice that were not pre-treated with clodronate-lip. In contrast to glycerolipoplex-mediated gene transfer, clodronate-lip pretreatment resulted in a strong decrease (23-fold for complexes containing plasmid pTG11033, 24-fold for complexes containing plasmid pCMV-Luc) of expression levels for i.v. injected polyplexes ( Figure 5 ). These observations suggest that clodronate-lip pretreatment may deplete (or modify) the cells in the lung that are normally transfected by PEI-polyplexes. Thus, it is possible that polyplexes transfect a different population of cells in the lung than lipoplexes. Alternatively, clodronate-lip may change the microenvironment of the lung or of serum components in such a way that uptake of polyplexes is inhibited. Although luciferase expression was observed in the lung, heart, spleen and liver of mice that were not treated with clodronate-lip, no significant levels of reporter gene expression were observed in these organs in clodronate-lip-treated mice (data not shown).
In conclusion, we demonstrate that pretreatment of mice with clodronate-lip can considerably enhance reporter gene expression after i.v. injection of lipoplexes containing cationic glycerolipids. On the other hand, expression levels are drastically reduced for i.v. injected polyplexes in clodronate-lip-pretreated mice. Although the mechanism of the enhancement effect is currently not understood, our observations indicate that for the efficiency of lipoplex-mediated gene delivery after i.v. injection, recirculation of complexes and/or the microenvironment of the lung could play an important role. The protocol described could be useful for preclinical development and evaluation of lipoplexes. Furthermore, a better understanding of the clodronate-lip enhancement effect may help to elucidate important parameters that are involved in the in vivo uptake of synthetic vectors.
